Company Statements
Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart
-
Thu, 11-Feb-2021
- Posted by: Biocon Biologics
No Comments
Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020
-
Fri, 25-Dec-2020
- Posted by: Biocon Biologics
Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart
-
Mon, 14-Dec-2020
- Posted by: Biocon Biologics
Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification
-
Tue, 12-May-2020
- Posted by: Biocon Biologics
Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed
-
Thu, 16-Apr-2020
- Posted by: Biocon Biologics
Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed
-
Wed, 01-Apr-2020
- Posted by: Biocon Biologics
Biocon’s Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
-
Sat, 22-Feb-2020
- Posted by: Biocon Biologics
U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru
-
Fri, 20-Sep-2019
- Posted by: Biocon Biologics
U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged
-
Sat, 31-Aug-2019
- Posted by: Biocon Biologics
U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru
-
Sat, 31-Aug-2019
- Posted by: Biocon Biologics
